Imatge de la portada

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

Proteolysis-targeting chimaeras (PROTACs) have been developed to be an emerging technology for targeted protein degradation and attracted the favour of academic institutions, large pharmaceutical enterprises, and biotechnology companies. The mechanism is based on the inhibition of protein function b...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autors principals:	Chao Wang (Autor), Yujing Zhang (Autor), Tingting Zhang (Autor), Lingyu Shi (Autor), Zhongmin Geng (Autor), Dongming Xing (Autor)
Format:	Llibre
Publicat:	Taylor & Francis Group, 2022-12-01T00:00:00Z.
Matèries:	article
Accés en línia:	Connect to this object online.
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
per: Chao Wang, et al.
Publicat: (2022)

Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug
per: BoRa Lee, et al.
Publicat: (2023)

PROTACs for BRDs proteins in cancer therapy: a review
per: Chao Wang, et al.
Publicat: (2022)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
per: Yujeong Moon, et al.
Publicat: (2023)

A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)
per: Robin Thomas Ulrich Haid, et al.
Publicat: (2023)

Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
per: Mingxing Hu, et al.
Publicat: (2020)

Design, synthesis, and bioevaluation of 1h-pyrrolo[3,2-c]pyridine derivatives as colchicine-binding site inhibitors with potent anticancer activities
per: Chao Wang, et al.
Publicat: (2024)

PROTACs targeting epigenetic proteins
per: Chao Zhang, et al.
Publicat: (2023)

Proteostasis and Proteolysis
Publicat: (2022)

Proteostasis and Proteolysis
Publicat: (2022)

Preimplantation chromosomal mosaics, chimaeras and confined placental mosaicism
per: John D West, et al.
Publicat: (2022)

The clinical advances of proteolysis targeting chimeras in oncology
per: Hao Xie, et al.
Publicat: (2021)

Neuroplasticity and Extracellular Proteolysis
per: Leszek Kaczmarek
Publicat: (2016)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
per: Sinan Ma, et al.
Publicat: (2022)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
per: Arvind Negi, et al.
Publicat: (2022)

Design, synthesis, and biological evaluation of biotinylated colchicine derivatives as potential antitumor agents
per: Chao Wang, et al.
Publicat: (2022)

PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer
per: Yulu Zhang, et al.
Publicat: (2024)

PROTAC technology as a novel tool to identify the target of lathyrane diterpenoids
per: Yanli Wu, et al.
Publicat: (2022)

Research advances of proteolysis targeting chimeras for acute kidney injury
per: Jun-dan Jia, et al.
Publicat: (2024)

Disseminated Mycobacterium chimaera infection favoring the development of Kaposi's sarcoma: a case report
per: Tommaso Clemente, et al.
Publicat: (2022)

In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera.
per: Sacha J Pidot, et al.
Publicat: (2021)

PROTAC technology for the treatment of Alzheimer's disease: advances and perspectives
per: Hiroyuki Inuzuka, et al.
Publicat: (2022)

3-aryl-4-(3,4,5-trimethoxyphenyl)pyridines inhibit tubulin polymerisation and act as anticancer agents
per: Chao Wang, et al.
Publicat: (2024)

Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs
per: Ponien Kou, et al.
Publicat: (2023)

On Digestive Proteolysis Being the Cartwright Lectures for 1894
per: Chittenden, R. H. (Russell Henry), 1856-1943

Perlecan and the Blood-Brain Barrier: Beneficial Proteolysis?
per: Jill eRoberts, et al.
Publicat: (2012)

Proteolysis-targeting chimeras and their implications in breast cancer
per: Angeles C. Tecalco-Cruz, et al.
Publicat: (2021)

Characteristic roadmap of linker governs the rational design of PROTACs
per: Yawen Dong, et al.
Publicat: (2024)

LncRNA AFAP1-AS1 Promotes Oral Squamous Cell Carcinoma Development by Ubiquitin-Mediated Proteolysis
per: Bao-Jun Li, et al.
Publicat: (2024)

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
per: Siqi Wang, et al.
Publicat: (2024)

Case report: Mycobacterium chimaera-induced lymph node infection in a patient with chronic myeloproliferative neoplasm misdiagnosed as tuberculous lymphadenitis
per: Yingqian Sun, et al.
Publicat: (2024)

Exploring Carbohydrates for Therapeutics: A Review on Future Directions
per: Jie Wang, et al.
Publicat: (2021)

Computational strategies for PROTAC drug discovery
per: Jia Wu, et al.
Publicat: (2023)

Degradation of proteins by PROTACs and other strategies
per: Yang Wang, et al.
Publicat: (2020)

PROTACs: Walking through hematological malignancies
per: Lara J. Bou Malhab, et al.
Publicat: (2023)

Are we ready to design oral PROTACs®?
per: Diego Garcia Jimenez, et al.
Publicat: (2021)

Application of PROTACs in target identification and validation
per: Yang Liu, et al.
Publicat: (2024)

Design, synthesis and biological evaluation of novel diarylpyridine derivatives as tubulin polymerisation inhibitors
per: Shanbo Yang, et al.
Publicat: (2022)

PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
per: Peiyi Zhang, et al.
Publicat: (2020)

Mycobacterium chimaera infections in cardiothoracic surgery patients exposed to heating and cooling devices despite infection control measures
per: Jensie Burton, et al.
Publicat: (2023)